- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01359020
Ibuprofen, Acetaminophen and Dipyrone to Fever Control in Children
May 23, 2011 updated by: Mantecorp Industria Quimica e Farmaceutica Ltd.
Randomized, Open Label, Comparative, Parallel, Multicenter Trial to Determinate the Efficacy Anf Tolerability of Ibuprofen, Acetaminophen and Dipyrone Drops to Fever Control in Children
The purpose of this study was to compare the efficacy and tolerability of acetaminophen, dipyrone and ibuprofen to fever control in children.
For the efficacy asses were compared:
- the time to start the action;
- the action duration;
- the difference between the basal temperature and the lower temperature in the study period.
For the tolerability asses all adverse events were recorded, as well as your intensity and the relation to the treatment.
Study Overview
Study Type
Interventional
Enrollment (Actual)
396
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pernambuco
-
Recife, Pernambuco, Brazil, 50070-550
- Instituto de Medicina Integral Professor Fernando Figueira
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 months to 6 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- male and female children aged 06 months to 06 years old, weight above 5 kilo and axillary temperature above 37,5 celsius degree.
Exclusion Criteria:
- patients with a bad general heath state
- patients with neoplasia, pepic ulcer, gastrointestinal bleeding,history of fever convulsion;
- intolerant to dypirone, ibuprofen, acetaminophen or any other nonsteroidal antiinflammatory drug;
- moderated or severe dehydration;
- conscience state alteration;
- not capable of ingest oral drugs;
- patients being treated with steroids;
- patients treated with antiinflammatory, analgesic and antipyretic drugs in the last 06 hours before the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ibuprofen
10 milligram per kilo, oral administration
|
The dosage for the three drugs was the same: 10 milligrams per kilo, oral administration
|
Active Comparator: Acetaminophen
10 milligram per kilo, oral administration
|
The dosage for the three drugs was the same: 10 milligrams per kilo, oral administration
|
Active Comparator: Dipyrone
10 milligram per kilo, oral administration
|
The dosage for the three drugs was the same: 10 milligrams per kilo, oral administration
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Antipyretic efficacy
Time Frame: Temperature was verified 15, 30, 45 and 60 minutes, 2, 3, 4, 5, 6, 7 and 8 hours after the administration of the drug.
|
The antipyretic efficacy was assessed comparing the time to the beggining of the action of the drugs, the difference between the final and inicial temperature and time of action.
|
Temperature was verified 15, 30, 45 and 60 minutes, 2, 3, 4, 5, 6, 7 and 8 hours after the administration of the drug.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events
Time Frame: Adverse Events were verified at 15, 30, 45 and 60 minutes, 2, 3, 4, 5, 6, 7 and 8 hours after the administration of the drug.
|
All adverse events were recorded.
|
Adverse Events were verified at 15, 30, 45 and 60 minutes, 2, 3, 4, 5, 6, 7 and 8 hours after the administration of the drug.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Claudia Patrícia DN Moura, Mantecorp Industria Quimica e Farmaceutica Ltda.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2007
Primary Completion (Actual)
March 1, 2008
Study Completion (Actual)
March 1, 2008
Study Registration Dates
First Submitted
May 20, 2011
First Submitted That Met QC Criteria
May 23, 2011
First Posted (Estimate)
May 24, 2011
Study Record Updates
Last Update Posted (Estimate)
May 24, 2011
Last Update Submitted That Met QC Criteria
May 23, 2011
Last Verified
May 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Body Temperature Changes
- Fever
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Antipyretics
- Acetaminophen
- Ibuprofen
- Dipyrone
Other Study ID Numbers
- ALI/P/04-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fever
-
Meir Medical CenterCompleted
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Sanofi Pasteur, a Sanofi CompanyCompletedYellow Fever | Dengue | Dengue Fever | Dengue Hemorrhagic FeverUnited States
-
U.S. Army Medical Research and Development CommandBausch Health Americas, Inc.WithdrawnCrimean-Congo Hemorrhagic Fever | Lassa FeverGermany
-
The Scientific and Technological Research Council...MonitorCROCompleted
-
Sanofi Pasteur, a Sanofi CompanyUnited States Department of DefenseCompletedDengue | Dengue Fever | Dengue Hemorrhagic FeverUnited States
-
Tongji HospitalRecruitingHFRS (Hemorrhagic Fever With Renal Syndrome)China
-
Shaare Zedek Medical CenterCompleted
-
Centre Hospitalier Universitaire de la RéunionCompleted
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic FeverSingapore
Clinical Trials on ibuprofen, dipyrone, acetaminophen
-
University Center of AraraquaraUniversity of Sao PauloCompletedPain, Postoperative
-
Ruhr University of BochumPfizerCompleted
-
Reckitt Benckiser LLCPremier Research Group plc; Aptuit Inc.CompletedPost-operative PainUnited States
-
Instituto Materno Infantil Prof. Fernando FigueiraCompleted
-
Washington University School of MedicineCompletedPain, Postoperative | Tonsillitis | Tonsillar HypertrophyUnited States
-
Ullevaal University HospitalUniversity of OsloCompleted
-
Wolfson Medical CenterUnknownPostoperative Pain | Post-Cesarean SectionIsrael
-
Alexander Payatakes, M.D.TerminatedTrigger Finger | Carpal Tunnel | De Quervain Disease | Ganglion CystUnited States